Last Updated on September 30, 2024 by The Health Master
DPCO
The Indian pharmaceutical industry, a cornerstone of the country’s healthcare sector, has been grappling with a significant challenge: the burdensome legal proceedings arising from the Drugs (Prices Control) Order (DPCO).
This government regulation, designed to control the pricing of essential medicines, has led to numerous disputes and prolonged litigation, hindering the industry’s growth and development.
A Decade-Long Legal Nightmare
The DPCO, introduced in various forms over the years, has been a source of contention between the pharmaceutical industry and the government.
Companies have faced a barrage of legal cases alleging non-compliance with the order’s provisions, such as failing to display price lists or refusing to sell medicines to dealers.
These cases have often dragged on for years, tying up valuable resources and diverting attention from the core business of providing affordable medicines.
Need for a New Approach
In an attempt to address the mounting legal disputes, the government had previously proposed a Special One Time Settlement (SOTS) scheme.
This initiative aimed to resolve cases through a one-time financial penalty, but it failed to gain traction.
Recognizing the need for a more comprehensive solution, industry bodies are now advocating for a revamped SOTS scheme.
Proposed Reforms: Decriminalization and SOTS
The industry’s recommendations include:
- Decriminalization of certain offenses: Cases related to minor violations, such as not displaying price lists, could be resolved through financial penalties rather than criminal proceedings.
- Expanded SOTS scheme: The SOTS scheme should cover all versions of the DPCO and include a wider range of offenses, including overcharging.
- Time-bound resolution: Cases under the SOTS scheme should be settled within a year of the alleged violation.
Misuse of DPCO Provisions
Pharmaceutical companies have also raised concerns about the misuse of certain DPCO provisions by stockists.
Some stockists have been using the threat of legal action to secure favorable terms, hindering the smooth functioning of the supply chain.
A Balanced Approach
The pharmaceutical industry is urging the government to adopt a balanced approach that ensures compliance with the DPCO while promoting industry growth.
By implementing the proposed reforms, the government can create a more conducive environment for the industry to operate, leading to better access to affordable medicines for Indian consumers.
Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.
Pharma Industry seeks amendments to DPCO 2013
DPCO: Govt Fines Pharma Companies Over Rs 8,500 Crore
DPCO 2013: Form 2, 4 & 5 amended to add details including GST rate
DPCO 2013: Pharma Industry urges Govt to revisit Para 18(1) and Para 13(2)
QR Code Mandate: Pharma Industry calls for Financial Support
Drug recall: Baxter recalls various batches of Tisseel due to dissolution time
USFDA approval granted for Theophylline Extended-Release Tablets
Pharma Retailers demand redesign of medicine packs: Strip Cutting
USFDA inspection with positive VAI to Dr. Reddy’s Lab for its API facility
Govt issues new uniform code for marketing of Medical Devices
Over 340 Pharma Companies overdue for USFDA inspection in India and China
APTI demands reservation of all Pharma Jobs for Pharmacy Graduates
Pharma Breakthrough: India starts producing API Clavulanic Acid
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
